Intellectual Property

XEPTAGEN's research results are protected through international patents.

Combinatorial Proteomic XEPTAGEN S.p.A. Registered Trade Mark No 14515D/2002
Combinatorial Proteomic XEPTAGEN S.p.A. Italian Application No PD2001C744

Polyclonal Antibodies XEPTAGEN S.p.A. PCT/IT01/393
Anticorpi Policlonali XEPTAGEN S.p.A. Italian Application No PD2000A000192
Covers the use of polyclonal and monoclonal antibodies against SCCA1 variants for liver cancer diagnosis from liver biopsies.

Specific method for cancer detection XEPTAGEN S.p.A. PCT /IT04/583
Metodo di diagnosi altamente specifico per neoplasie XEPTAGEN S.p.A. Italian Application No PD2003A000264
The determination of biomarkers-IgM immunocomplexes by using monoclonal or polyclonal antibodies against biomarkers for cancer detection from serum. The patent covers the determination of all the known cancer biomarkers as IgM immunocomplexs.

Method and device for detecting neoplastic and preneoplastic cells XEPTAGEN S.p.A. PCT in preparation
Metodo e dispositivi per la rilevazione della presenza di cellule neoplastiche e pre-neoplastiche XEPTAGEN S.p.A. Italian Application No PD2004A000212.
Covers the simultaneous co-determination of all known biomarker-IgM immunocomplexes by using multiplex technology (compleXima biochip) for cancer detection.

Method for the preparation of immunoconjugates and use thereof XEPTAGEN S.p.A. PCT/IB2008/054203-WO/2010/043927.
Method for the preparation of molecular conjugates comprising immunoglobulins and biomarkers occurring in neoplastic diseases characterized by high levels of reproducibility.

Method for measuring values indicating cancer XEPTAGEN S.p.A. European Application No EP 10182565.
Covers the determination of CEA-IgM immunocomplexes by using monoclonal or polyclonal antibodies against CEA for colorectal cancer detection from patient sera.

Method for measuring values indicating cancer XEPTAGEN S.p.A. European Application No EP 10178983.
Covers the determination of PSA-IgM immunocomplexes by using monoclonal or polyclonal antibodies against PSA for prostate cancer detection from patient sera.

Method for prostate cancer diagnosis. XEPTAGEN S.p.A. Italian Application No PD2011A000323.
Covers a method to reduce the number of negative prostatic mappings based on the determination of PSA-IgM from patient sera and other physiological parameters.